文献速递胸部肿瘤

非小细胞肺癌冷冻消融的免疫学效应:综述

Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
PubMed 文献 · J Thorac Oncol · 2018-01-31

本文综述了原发肺肿瘤冷冻消融的临床前与临床研究,探讨冷冻消融诱导的抗肿瘤免疫反应强度及其与免疫治疗或分子靶向治疗的协同作用。文章进一步论证了将冷冻消融联合免疫检查点抑制剂用于晚期肺癌治疗的理论依据,该策略正在临床研究中。

要点

  • 冷冻消融可诱导抗肿瘤免疫反应,与免疫检查点抑制剂联用具理论协同基础。
  • 冷冻消融与免疫治疗或靶向治疗的联合策略正在临床探索中。
  • 联合策略旨在改善晚期肺癌的治疗反应。

核心结论

  • 冷冻消融联合免疫检查点抑制剂治疗晚期肺癌具有理论依据,目前正在临床研究中。

研究设计与样本

  • 综述了原发肺肿瘤冷冻消融的临床前和临床研究。

主要发现

  • 冷冻消融可诱导抗肿瘤免疫反应。
  • 冷冻消融与免疫治疗或分子靶向治疗联合可能协同改善治疗反应。

临床怎么用

  • 可考虑将冷冻消融与免疫检查点抑制剂联合用于晚期肺癌的临床研究或治疗探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In cryoimmunotherapy, target tumors are treated with cryoablation to generate antitumor immune responses. Because immune checkpoint inhibitors have demonstrated that lung cancer can be an immunotherapy-responsive disease, there has been renewed interest in the immunological aspects of cryoablation of lung cancer. Herein, we review preclinical and clinical trials of cryoablation of primary lung tumors. We examine the magnitude of cryoablation-induced antitumor immune responses and the synergy between cryoablation and either other immunotherapies or molecular targeted therapies to improve treatment responses in advanced lung cancer. We further discuss a rationale for the addition of cryoablation to immune checkpoint inhibitors for the treatment of advanced lung cancer, which is currently under clinical investigation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Katzman D, Wu S, Sterman DH, et al. Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review. J Thorac Oncol. 2018. PMID: 29391289. doi:10.1016/j.jtho.2018.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。